Predictive preclinical models designed to transform drug development
We build patient-derived experimental models and integrate them with deep clinical, omics and digital-pathology data — so preclinical validation becomes genuinely predictive and clinically relevant.
Agile, clinically relevant preclinical testing
An integrated patient-derived platform for target identification, compound evaluation and in vitro efficacy — supporting biotech and pharma across early discovery and translational research.
Advanced experimental models
Patient-anchored analysis
Preclinical prediction
Our models are anchored in deep patient data
Generalist providers sell standardized models with limited data. We start from real patient samples and keep the clinical context attached.
- Standardized models
- Limited accompanying data
- Low predictive value
- Models derived from real patient samples
- Anonymized clinical data
- Digital pathology and histopathology
- Omics data (genomics, transcriptomics)
This integration enables analysis of associations between phenotypes, histological patterns and experimental response — radically increasing predictive value.
Our first agreement validates demand in a highly complex niche
With the INCITE Foundation we are developing preclinical models based on cell lines from liposarcoma patients — a very low-incidence tumor. The collaboration connects us to an international network of institutions and companies dedicated to liposarcoma research.
Start a collaboration Patient-derived liposarcoma models, developed alongside an international research network.